{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:05:24Z","timestamp":1792710324142,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer BV","doi-asserted-by":"publisher","award":["WI229707"],"award-info":[{"award-number":["WI229707"]}],"id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland GmbH & Co KG","doi-asserted-by":"publisher","award":["SA-003854"],"award-info":[{"award-number":["SA-003854"]}],"id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["1711+02014"],"award-info":[{"award-number":["1711+02014"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ard.2025.11.019","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T04:29:03Z","timestamp":1766032143000},"page":"620-629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5280-2182","authenticated-orcid":false,"given":"Agnes E.\u202fM.","family":"Looijen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2361-2803","authenticated-orcid":false,"given":"Paco M.\u202fJ.","family":"Welsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5248","authenticated-orcid":false,"given":"Sytske Anne","family":"Bergstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8572-1437","authenticated-orcid":false,"given":"Annette H.\u202fM.","family":"van der Helm-van Mil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-6222","authenticated-orcid":false,"given":"Pascal H.\u202fP.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.11.019_bib0003","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ard.2025.11.019_bib0004","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/rheumatology\/keac708","article-title":"Controversies in rheumatology: telemedicine-friend or foe?","volume":"62","author":"Dejaco","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.ard.2025.11.019_bib0005","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41584-024-01177-7","article-title":"Rheumatology in the digital health era: status quo and quo vadis?","volume":"20","author":"Knitza","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.11.019_bib0006","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40744-020-00237-0","article-title":"Implementation and evaluation of audit and feedback for monitoring treat-to-target (T2T) strategies in rheumatoid arthritis using performance measures","volume":"7","author":"Barber","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"8","key":"10.1016\/j.ard.2025.11.019_bib0007","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2022-222341","article-title":"2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases","volume":"81","author":"De Thurah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.11.019_bib0008","doi-asserted-by":"crossref","first-page":"f167","DOI":"10.1136\/bmj.f167","article-title":"Patient reported outcome measures could help transform healthcare","volume":"346","author":"Black","year":"2013","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ard.2025.11.019_bib0009","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1136\/annrheumdis-2018-214199","article-title":"Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis","volume":"78","author":"Ferreira","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ard.2025.11.019_bib0010","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/acr.23799","article-title":"International consortium for health outcome measurement set of outcomes that matter to people living with inflammatory arthritis: consensus from an international working group","volume":"71","author":"Oude Voshaar","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002093","article-title":"Patient reported outcome measures for rheumatoid arthritis disease activity: a systematic review following COSMIN guidelines","volume":"8","author":"Pickles","year":"2022","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.ard.2025.11.019_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000202","article-title":"Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis","volume":"2","author":"Hendrikx","year":"2016","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.ard.2025.11.019_bib0013","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.ard.2025.11.019_bib0014","first-page":"186","article-title":"Psychometric properties of an index of three patient reported outcome (PRO) measures, termed the CLinical ARthritis Activity (PRO-CLARA) in patients with rheumatoid arthritis. The NEW INDICES study","volume":"28","author":"Salaffi","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.11.019_bib0015","article-title":"Rheumatoid arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures","volume":"92","author":"Salaffi","year":"2021","journal-title":"Acta Biomed"},{"issue":"4","key":"10.1016\/j.ard.2025.11.019_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004687","article-title":"Combining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritis","volume":"10","author":"Looijen","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41687-023-00554-2","article-title":"Facilitators and barriers to implementing electronic patient-reported outcome and experience measures in a health care setting: a systematic review","volume":"7","author":"Glenwright","year":"2023","journal-title":"J Patient Rep Outcomes"},{"issue":"3","key":"10.1016\/j.ard.2025.11.019_bib0018","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ard.2025.11.019_bib0019","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.11.019_bib0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2474-10-71","article-title":"Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial","volume":"10","author":"Claessen","year":"2009","journal-title":"BMC Musculoskelet Disord"},{"issue":"7","key":"10.1016\/j.ard.2025.11.019_bib0021","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/annrheumdis-2013-204788","article-title":"Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial","volume":"73","author":"de Jong","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.11.019_bib0022","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/annrheumdis-2018-214970","article-title":"Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study","volume":"78","author":"van Mulligen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0023","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/keq230","article-title":"Predicting arthritis outcomes\u2014what can be learned from the Leiden Early Arthritis Clinic?","volume":"50","author":"de Rooy","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ard.2025.11.019_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003296","article-title":"Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands","volume":"17","author":"Matthijssen","year":"2020","journal-title":"PLOS Med"},{"issue":"4","key":"10.1016\/j.ard.2025.11.019_bib0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.ard.2025.11.019_bib0026","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3899\/jrheum.2024-1258","article-title":"Sex differences in rheumatoid arthritis: new insights from clinical and patient-reported outcome perspectives","volume":"52","author":"Koc","year":"2025","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.11.019_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274264","article-title":"Disease activity trajectories for early and established rheumatoid arthritis: real-world data from a rheumatoid arthritis cohort","volume":"17","author":"Movahedi","year":"2022","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ard.2025.11.019_bib0028","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00296-015-3271-8","article-title":"Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis","volume":"35","author":"Katchamart","year":"2015","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.ard.2025.11.019_bib0029","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar4540","article-title":"Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study","volume":"16","author":"Innala","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"5 Suppl 39","key":"10.1016\/j.ard.2025.11.019_bib0030","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0031","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/ard.2006.059451","article-title":"Consensus Dutch health assessment questionnaire","volume":"66","author":"Boers","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.11.019_bib0032","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ard.2025.11.019_bib0033","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3899\/jrheum.110392","article-title":"It\u2019s good to feel better but it\u2019s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10","volume":"38","author":"Strand","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.11.019_bib0034","series-title":"STATA LASSO reference manual","year":"2021"},{"issue":"2","key":"10.1016\/j.ard.2025.11.019_bib0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.11613\/BM.2015.015","article-title":"Understanding Bland Altman analysis","volume":"25","author":"Giavarina","year":"2015","journal-title":"Biochem Med"},{"issue":"2","key":"10.1016\/j.ard.2025.11.019_bib0036","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/096228029900800204","article-title":"Measuring agreement in method comparison studies","volume":"8","author":"Bland","year":"1999","journal-title":"Stat Methods Med Res"},{"issue":"5 Suppl 46","key":"10.1016\/j.ard.2025.11.019_bib0037","first-page":"S22","article-title":"Disease activity measures for rheumatoid arthritis","volume":"25","author":"Dougados","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.11.019_bib49","unstructured":"Dankers F.J.W.M., Traverso A., Wee L., et al. Prediction modeling methodology. 2018. In: Kubben P., Dumontier M., Dekker A., editors. Fundamentals of Clinical Data Science [Internet]. Cham (CH): Springer; 2019. Chapter 8. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK543534\/"},{"key":"10.1016\/j.ard.2025.11.019_bib0038","series-title":"Applied logistic regression","author":"Hosmer","year":"2013"},{"issue":"6","key":"10.1016\/j.ard.2025.11.019_bib50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/emermed-2017-206735","article-title":"What is an ROC curve?","volume":"34","author":"Hoo","year":"2017","journal-title":"Emerg Med J"},{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002885","article-title":"Hand function is already reduced before RA development and reflects subclinical tenosynovitis","volume":"9","author":"Krijbolder","year":"2023","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.ard.2025.11.019_bib0040","doi-asserted-by":"crossref","first-page":"rkae143","DOI":"10.1093\/rap\/rkae143","article-title":"Single-camera motion capture of finger joint mobility as a digital biomarker for disease activity in rheumatoid arthritis","volume":"9","author":"Venerito","year":"2025","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"10.1016\/j.ard.2025.11.019_bib0041","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s10067-022-06162-7","article-title":"The RAPID3 questionnaire as a screening tool to reduce the number of outpatient clinic visits: a retrospective cohort study","volume":"41","author":"Wiegel","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0042","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semarthrit.2018.12.006","article-title":"The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life","volume":"49","author":"Scott","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ard.2025.11.019_bib0043","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3899\/jrheum.110401","article-title":"Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop","volume":"38","author":"Bingham","year":"2011","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.11.019_bib0044","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3899\/jrheum.110400","article-title":"Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group","volume":"38","author":"Alten","year":"2011","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2025.11.019_bib0045","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/annrheumdis-2011-200343","article-title":"The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review","volume":"71","author":"Bombardier","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0046","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2288-10-22","article-title":"The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content","volume":"10","author":"Mokkink","year":"2010","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0047","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ard.2025.11.019_bib0048","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:20:22Z","timestamp":1780820422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725045510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0003496725045510"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.11.019","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}